Cargando…

Anticancer activity and chemoprevention of xenobiotic organosulfurs in preclinical model systems

There seems to be little doubt that xenobiotic and plant derived organosulfur compounds have enormous benefits for in vitro cellular functions and for a multitude of diseases, including cancer. Since there are numerous reviews on anticancer activities of plant organosulfurs, the focus herein will be...

Descripción completa

Detalles Bibliográficos
Autor principal: Click, Robert E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222532/
https://www.ncbi.nlm.nih.gov/pubmed/25383193
http://dx.doi.org/10.7243/2052-6199-1-4
_version_ 1782343050860691456
author Click, Robert E.
author_facet Click, Robert E.
author_sort Click, Robert E.
collection PubMed
description There seems to be little doubt that xenobiotic and plant derived organosulfur compounds have enormous benefits for in vitro cellular functions and for a multitude of diseases, including cancer. Since there are numerous reviews on anticancer activities of plant organosulfurs, the focus herein will be on alterations associated with xenobiotic organosulfurs. Benefits of 2-mercaptoethanol (2-Me), N-Acetyl-cysteine, cysteamine, thioproline, piroxicam, disulfiram, amifostine, sulindac, celecoxib, oltipraz and their derivates on transplanted homologous tumors and on autochthonous cancers with a viral-, radiation-, chemical carcinogen-, and undefined-etiology are assessed. Because all organosulfurs were not tested for activity in each of the etiology categories, comparative evaluations are restricted. In general, all ‘appeared’ to lower the incidence of cancer irrespective of etiology; however, since most of these values were determined at ages much younger than at a natural-end-of-life-age, differences most likely, instead, reflect a delayed initiation and/or a slowed progression of tumorigenesis. The poorest, long-term benefits of early intervention protocols occurred for viral- and chemical carcinogen-induced cancers. In addition, once tumorigenesis was beyond the initiation stage, outcomes of organosulfur therapies were extremely poor, indicating that they will not be of significant value as stand alone treatments. More importantly, except for the lifetime prevention of spontaneous and radiation-induced mammary tumors by daily dietary 2-Me, similar life long prevention of tumorigenesis was not achieved with other xenobiotics or any of nature’s plant organosulfurs. These results raise an interesting question: Is the variability in incidence found for different organosulfurs associated with (a) their structure, (b) the length of the untreated latency period, (c) treatment duration/dose, and/or (d) the etiology-inducing agent?
format Online
Article
Text
id pubmed-4222532
institution National Center for Biotechnology Information
language English
publishDate 2013
record_format MEDLINE/PubMed
spelling pubmed-42225322014-11-06 Anticancer activity and chemoprevention of xenobiotic organosulfurs in preclinical model systems Click, Robert E. Oncol Discov Article There seems to be little doubt that xenobiotic and plant derived organosulfur compounds have enormous benefits for in vitro cellular functions and for a multitude of diseases, including cancer. Since there are numerous reviews on anticancer activities of plant organosulfurs, the focus herein will be on alterations associated with xenobiotic organosulfurs. Benefits of 2-mercaptoethanol (2-Me), N-Acetyl-cysteine, cysteamine, thioproline, piroxicam, disulfiram, amifostine, sulindac, celecoxib, oltipraz and their derivates on transplanted homologous tumors and on autochthonous cancers with a viral-, radiation-, chemical carcinogen-, and undefined-etiology are assessed. Because all organosulfurs were not tested for activity in each of the etiology categories, comparative evaluations are restricted. In general, all ‘appeared’ to lower the incidence of cancer irrespective of etiology; however, since most of these values were determined at ages much younger than at a natural-end-of-life-age, differences most likely, instead, reflect a delayed initiation and/or a slowed progression of tumorigenesis. The poorest, long-term benefits of early intervention protocols occurred for viral- and chemical carcinogen-induced cancers. In addition, once tumorigenesis was beyond the initiation stage, outcomes of organosulfur therapies were extremely poor, indicating that they will not be of significant value as stand alone treatments. More importantly, except for the lifetime prevention of spontaneous and radiation-induced mammary tumors by daily dietary 2-Me, similar life long prevention of tumorigenesis was not achieved with other xenobiotics or any of nature’s plant organosulfurs. These results raise an interesting question: Is the variability in incidence found for different organosulfurs associated with (a) their structure, (b) the length of the untreated latency period, (c) treatment duration/dose, and/or (d) the etiology-inducing agent? 2013 /pmc/articles/PMC4222532/ /pubmed/25383193 http://dx.doi.org/10.7243/2052-6199-1-4 Text en © 2013 Robert E. Click licensee Herbert Publications Ltd This is an Open Access article distributed under the terms of Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0). This permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Click, Robert E.
Anticancer activity and chemoprevention of xenobiotic organosulfurs in preclinical model systems
title Anticancer activity and chemoprevention of xenobiotic organosulfurs in preclinical model systems
title_full Anticancer activity and chemoprevention of xenobiotic organosulfurs in preclinical model systems
title_fullStr Anticancer activity and chemoprevention of xenobiotic organosulfurs in preclinical model systems
title_full_unstemmed Anticancer activity and chemoprevention of xenobiotic organosulfurs in preclinical model systems
title_short Anticancer activity and chemoprevention of xenobiotic organosulfurs in preclinical model systems
title_sort anticancer activity and chemoprevention of xenobiotic organosulfurs in preclinical model systems
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222532/
https://www.ncbi.nlm.nih.gov/pubmed/25383193
http://dx.doi.org/10.7243/2052-6199-1-4
work_keys_str_mv AT clickroberte anticanceractivityandchemopreventionofxenobioticorganosulfursinpreclinicalmodelsystems